A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. AbCellera Biologics Inc’s current trading price is -64.22% away from its 52-week high, while its distance from the 52-week low is 6.27%. The stock’s price range for this time frame has been between $2.71 and $8.05. The trading volume of the company’s shares in the Healthcare reached around 1.94 million for the day, which was evidently higher than the average daily volume of 1.51 million over the last three months.
The market performance of AbCellera Biologics Inc has been somewhat unstable. Over the past year, the company’s stock achieved a high of $8.05 on 07/19/23, with the lowest value for the same timeframe being $2.71, recorded on 06/25/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
AbCellera Biologics Inc (ABCL) has experienced a quarterly decline of -35.86% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 846.86M and boasts a workforce of 586 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.22, with a change in price of -2.13. Similarly, AbCellera Biologics Inc recorded 1,511,084 in trading volume during the last 100 days, posting a change of -42.51%.
How ABCL’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ABCL stands at 0.07. Similarly, the long-term debt-to-equity ratio is also 0.06.
ABCL Stock Stochastic Average
AbCellera Biologics Inc’s raw stochastic average for the past 50 days is currently at 10.43%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 11.41%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 6.00% and 4.07%, respectively.
ABCL Stock Price Performance Analysis
The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. This year’s metric has recorded a Price decrease of -49.56%. However, over the past six months, we’ve seen a stronger performance of -50.09%. The price of ABCL leaped by -29.41% over the last 30 days. And in the last five days, it has fallen by -2.04%.
